B2BROKER
The latest major upgrade to B2Core was just released by B2Broker, significantly enhancing the platform's back-office and CRM solutions. The V2.1 upgrade delivers on the highly anticipated savings feature, introduces a new trading platform and PSP integrations, and drastically improves the user experience on the platform. Let’s explore:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404452158/en/
B2Broker, a leading liquidity and technology provider, has just announced the release of a new version of B2Core, its sophisticated CRM and back-office solution. B2Core V2.1 integrates the TradeLocker trading platform inside its ecosystem, adds new PSPs and enhances the existing ones, and upgrades its UI. (Photo: Business Wire)
Polished UI & Peak Performance
Version 2.1 of B2Core brings a new user interface, major functionality improvements, and technical fixes.
- A Withdrawal summary provides comprehensive transfer information that features commissions, exchange rates and the net transaction amount.
- Account creation now enforces minimum deposit settings to maintain consistency in the back-office.
- On the Deposit, Withdraw, and Transfer pages, accounts in selectors are now categorised by type (e.g., Fiat, Coins, MT4, MT5) for easier navigation.
- Platform consistency is guaranteed by the Unified Date Format.
- The old and new UI settings can now be easily switched by users.
Integration with TradeLocker Trading Platform
B2Core introduces TradeLocker, an innovative trading platform seamlessly integrated into the trader's room. This addition enhances the company’s existing suite of integrated platforms, including MetaTrader 4, MetaTrader 5, cTrader and B2Trader, offering brokerages a complex set of trading solutions.
TradeLocker presents a comprehensive suite of powerful trading tools and instruments aiming to cater to a wide spectrum of clients, from novices to seasoned traders. The platform is equipped with versatile features designed to support a variety of trading strategies and preferences, facilitating a seamless and efficient trading experience for brokerage clients.
TradeLocker integrates with TradingView to offer a sophisticated charting capability, granting users access to an extensive array of customisable charts and indicators. The platform provides traders with modern tools to manage risks effectively.
Among its standout features are SL & TP Calculator, On-Chart Trading, One-click Trading, Trailing Stop Loss, and Social Mode, enabling traders to efficiently manage their trades engaging with the market. Users can easily develop or customise bots, signals, indicators, and strategies using the TradeLocker AI at TradeLocker Studio.
Payment Improvements and Integrations
Thanks to the V2.1 B2Core update, users now have more transaction options, and the scope of payment integrations has expanded.
Sqala supports deposits and withdrawals in Brazilian reals (BRL). It is renowned for its simplicity, competitive exchange rates, and a convenient dashboard that provides all the essential data. By including Sqala in its portfolio, B2Broker has increased the range of its solutions and fulfilled the needs of customers worldwide.
Transactions have been streamlined and fortified through several new improvements:
- Within the B2Core environment, BridgerPay provides a better deposit process through an automated data fill-in feature that streamlines transaction processing.
- Praxis configuration has been enhanced to improve transaction security. To comply with diverse regulatory standards, you can now enable clients from various countries to submit specific documents.
- The constructor payment adjustments allow clients to attach documents for deposits and withdrawals, ensuring maximum compliance and record accuracy.
The V2.1 upgrade has also brought back access to 1-2-Pay and WireCustom for deposits and withdrawals to expand the choices for transfers.
Engage Customers with Savings Feature
Last but not least, V2.1 adds a savings feature that lets users invest idle funds and get interest over specific periods. The savings programs currently support fixed savings, allowing users to receive fixed-interest rewards. Moreover, admins can access, modify, and initiate new savings programs with the presets page, effortlessly incorporating both business and client preferences.
The savings feature offers flexibility across the board, allowing users to set customised annual interest rates and adjust investment duration with 30-day intervals (30, 60, or 90 days). Brokers may also impose an early withdrawal penalty to maintain the viability of their savings plans.
The savings feature is highly customisable and configurable. The annual interest earnings option will motivate the clients to retain their funds within the broker’s ecosystem. Additionally, it enables brokers to increase fund retention and liquidity within B2Core, resulting in an advantageous situation for everybody involved.
Final Remarks
B2Core continues B2Broker’s mission to deliver quality across all products and services, ensuring maximum client satisfaction. The V2.1 update is another testament to raising industry standards!
The team is working on the complete transition of B2Core to the new interface. Additionally, B2Core intends to offer flexible interest rates for the savings plans. The team also works hard to add new integrations and expansions, allowing clients to enjoy a comprehensive CRM and back-office solutions suite!
Explore B2Core’s new features today and discover the benefits for your business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404452158/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AdvanCell to participate in Jefferies Global Healthcare Conference in London11.11.2025 14:00:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025. The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion. “It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We loo
The Future Is Set for Tourism’s Next Era as the Inaugural TOURISE Summit Opens11.11.2025 13:51:00 CET | Press release
Nearly 8000 delegates register to attend the first TOURISE Summit being held 11-13 November140 global speakers set to take part With the bold ambition to rewrite the rules of travel, the inaugural TOURISE Summit under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister was officially opened today by H.E. Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111716065/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, opens the inaugural TOURISE Summit in Riyadh. TOURISE ushers in a new era for global tourism, uniting ministers, delegates, and visionaries from around the world as the premier platform dedicated to shaping the future of global tourism. Taking place from November 11-13, 2025, immediately following the 50th United Nations Tourism
Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 13:39:00 CET | Press release
The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower
Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 13:06:00 CET | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma11.11.2025 13:00:00 CET | Press release
Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
